Table 1 Retrospective studies evaluating the treatment of the primary tumor in breast cancer patients with synchronous metastases
From: Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases
Authors (ref) | Database | Years of inclusion | Local treatment | Number of patients total/local treatment/no local treatment | Characteristics associated with a higher OS rate in multivariate analysis | Multivariate Analysis of Overall Survival Hazards Ratio for Death (95%CI) with local treatment |
|---|---|---|---|---|---|---|
Kahn et al. [13] | National cancer database of the American college of surgeons | 1990-1993 | S | 16023/9162/6861 | S, systemic therapy, number of metastatic sites | HR OS (RO) = 0.61 (0.58-0.65) HR (R1) = 0.751 (0.71-0.793) |
Gnerlich et al. [11] | SEER | 1988-2003 | S | 9734/4578/5156 | Â | HR OS = 0.57 (0.55-0.60) |
Bafford et al. [7] | Dana Farber Cancer Institute, Brigham and Women's Hospital and Massachusetts General Hospital | 1998-2005 | S | 147/61/86 | S, ER+, Her2+, no CNS metastasis | HR OS = 0.47 (p = 0.003) |
Shien et al. [18] | National Cancer Center Hospital | 1962-2007 | S | 326/160/184 | S, age <50, soft tissue or bone metastasis | HR OS = 0.89 (0.79-1) |
Blanchard et al. [8] | Laboratory of the university of texas health science center | 1973-1991 | S | 395/242/153 | S, ER +, PR+, number of metastatic sites | HR OS = 0.609 (0.489-0.757) |
Fields et al. [10] | Washington university medical center | 1996-2005 | S | 409/287/222 | S, Bone only metastasis | HR OS = 0.53 (0.42-0.67) No difference in time to metastatic progression between the 2 groups |
Babiera et al. [6] | MD Anderson cancer center | 1997-2002 | S | 224/82/142 | Only one site of metastasis, HER2+, Caucasian ethnicity | HR OS = 0.5 (0.21-1.19) HR TTFP = 0.54 (0.38-0.77, p = 0.0007) |
Hazard et al. [12] | Lynn Sage Breast Center (Northwestern memorial Hospital) | 1995-2005 | S | 111/47/64 | NA | HR OS = 0.798 (p = 0.52) HR TTFP = 0.49 (p = 0.015) |
Cady et al. [9] | Massachusetts General Hospital and Birgham and Women's Hospital | 1970-2002 | S | 622/234/388 | Young age, RH +, bone only metastasis | Matched-pair analysis: benefit of surgery p < 0.0001 |
Ruiterkamp et al. [17] | Eindhoven Cancer Registry | 1993-2004 | S | 728/288/440 | Surgery, age, no more than one metastatic site, no concomitant disease(p = 0.06), systemic therapy | HR OS = 0.62 (95%CI = 0.51-0.76) |
Leung et al. [19] | Medical College of Virginia Campus of Virginia Commonwealth University, | 1990-2000 | S | 157/52/105 | Chemotherapy | No benefit in multivariate analysis |
Rapiti et al. [16] | Geneva cancer registry | 1977-1996 | S | 300/127/173 | Age < 60, none N3, ER+, none visceral metastasis, none CNS metastasis, hormonal treatment, surgery with negative margins | HR OS = 0.6 if R0 (0.4-1.0) NS if R1 |
Le Scodan et al. [14] | René Huguenin Cancer Center | 1984-2004 | RT | 581/320/261 | Only one metastatic site, young age, LRT, no visceral metastases, N0 | HR OS = 0.7 (0.58-0.85) |